Santo Domingo, RD.
The President of the Dominican Republic, Luis Abinader, asked his American counterpart Joe Biden not to allow the United States’ waiting for new trials of the AstraZeneca vaccine against covid-19 to delay its arrival in the Dominican Republic.
Abinader posted the message with a publication in the New York Times newspaper stating that the United States has millions of doses of the AstraZeneca vaccine pending the results of the trials, while the countries that have authorized the vaccine are asking for it. .
Pdte. @ JoeBiden, less developed countries and traditional American allies like the Dom. Rep., We have approved the AstraZeneca vaccine and we urgently need it. Don’t let the wait for new studies slow our immediate access to this vaccine. wouldn’t be fair ”, wrote Luis Abinader.
According to the paper, the clinical trial being conducted by the US has not yet yielded results, and the company has not filed for emergency use approval from the Food and Drug Administration (EMA). While AstraZeneca has asked the Biden government to allow it to lend US doses to the European Union, where it has failed to meet its original delivery obligations and where the vaccination campaign has been seriously stranded.
Faced with the complaint that the AstraZeneca vaccine could cause thromboembolic events, countries such as Italy, Denmark, Norway and Iceland, as well as Estonia, Lithuania, Latvia and Luxembourg, have decided to have the immunization with all its doses or with a specific batch only. to suspend. awaits the PRAC Committee of the European Medicines Agency to complete its investigation of the reported reaction cases.
While the Dominican Republic’s Cabinet of Health announced that from next Friday through 27 of this month, the vaccination process, which began on Feb. 16 after the arrival of the first batch of vaccines from India, will continue by appointment.
Likewise, the second dose will be administered from March 24.
Last October, Luis Abinader’s government signed an agreement with British company AstraZeneca to acquire 10 million doses of its AZD1222 vaccine, co-developed with the University of Oxford, for a value of $ 40 million.